We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Viralytics Fpo (delisted) | ASX:VLA | Australian Stock Exchange | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
From Apr 2019 to Apr 2024
By Colin Kellaher
Merck & Co. (MRK) Wednesday said it agreed to buy Australia's Viralytics Ltd. (VLA.AU) for about $394 million in cash in a deal that expands Merck's immuno-oncology pipeline.
Merck, based in Kenilworth, N.J., said it will pay 1.75 Australian dollars for each share of Viralytics, a Sydney-based company focused on oncolytic-immunotherapy treatments for a range of cancers. The deal represents a 160% premium to Viralytics's one-month volume weighted average share price.
Merck said it will gain full rights to Cavatak, Viralytics's investigational oncolytic immunotherapy, which is currently being evaluated in multiple Phase 1 and Phase 2 clinical trials, including in combination with Merck's Keytruda anti-PD-1 therapy. Under an agreement the companies announced in November 2015, a study is investigating the use of the Cavatak and Keytruda combination in melanoma, prostate, lung and bladder cancers.
Merck said it expects to complete the acquisition of Viralytics in the second quarter.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 21, 2018 06:26 ET (11:26 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Viralytics Chart |
1 Month Viralytics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
